Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Hypertension - Pipeline Review, H2 2013 market report to its offering
Hypertension - Pipeline Review, H2 2013
Summary
, 'Hypertension - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension. Hypertension - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hypertension.
- A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypertension pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned
Shionogi & Co., Ltd.
Sanofi-Aventis
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
BioLineRx, Ltd.
Novartis AG
Samyang Corporation
Biocon Limited
Chong Kun Dang Pharmaceutical
Daewoong Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
IntelGenx Technologies Corp.
Medivir AB
Compugen Ltd.
Palatin Technologies, Inc.
Cytokinetics, Inc
Yuhan Corporation
Torrent Pharmaceuticals Limited
Choongwae Pharma Corp
Hanall Pharmaceutical Co., Ltd.
Ahn-Gook Pharmaceutical Co., Ltd.
LG Life Sciences, Ltd
Panacea Biotec Limited
DiaMedica Inc.
DONGKOOK Pharmaceutical Co., Ltd.
AFFiRiS AG
Ache Laboratorios Farmaceuticos S/A
Anacor Pharmaceuticals, Inc.
AngioDesign
INNOPHARMAX, INC.
QUANTUM GENOMICS Corp.
vasopharm GmbH
Cellceutix Corporation
Diakron Pharmaceuticals, Inc.
Biolink Group AS
miRagen Therapeutics, Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
MicroDose Therapeutx, Inc.
Vicore Pharma AB
Kotobuki Pharmaceutical Co., Ltd.
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/140891/hypertension-pipeline-review-h2-2013.html